Organisation paid for research Program year 2023 Source: CMS Open Payments

Weill Med College

Neither a doctor nor a teaching hospital

Research payments

$427,289

23 payments

Through program year 2023, Weill Med College is reported as receiving $427,289 in research payments, across 23 payments.

By program year

4 rows
Year Kind Amount Payments
2023 Research $35,061 1
2021 Research $102,611 7
2020 Research $236,549 9
2019 Research $53,068 6

Breakdown

Who paid Research payments · program years 2019–2023
  1. Acerta Pharma LLC $280,719 4 payments
  2. AstraZeneca Pharmaceuticals LP $109,630 15 payments
  3. AstraZeneca UK Limited $36,940 4 payments
Studies the money was for Research payments · program years 2019–2023
  1. This study is a multicenter open label nonrandomized sequential group dose escalation study to assess safety tolerability pharmacokinetics and preliminary anti tumor activity of ascending doses of AZD5991 in subjects with relapsed or refractory hematologic malignancies $253,858 3 payments
  2. Study of MEDI4736 Durvalumab With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer $42,567 6 payments
  3. A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST) $35,061 1 payment
  4. A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy $26,861 1 payment
  5. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation $22,973 2 payments
  6. An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) $22,452 3 payments
  7. A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care $15,754 2 payments
  8. A Phase III Randomized Open Label Multi Center Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non Small Cell Lung Cancer NSCLC MYSTIC $3,885 1 payment
  9. Savolitinib vs Sunitinib in MET driven PRCC $2,000 1 payment
  10. Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy $1,754 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record